7-氟-2(1H)-喹喔啉酮 | 145323-53-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 7-氟-2(1H)-喹喔啉酮
• 中文别名: 7-氟喹-2(1H)-酮
• 英文名称: 7-fluoroquinoxalin-2(1H)-one
• 英文别名: 7-fluoro-1H-quinoxalin-2-one
• CAS: 145323-53-1
• 化学式: C₈H₅FN₂O
• 分子量: 164.139
• InChiKey: WQSBOFHCYAGWJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-氟-2(1H)-喹喔啉酮 在 sodium hydride 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.75h， 生成 1-(2-(4-aminopiperidin-1-yl)ethyl)-7-fluoroquinoxalin-2(1H)-one
  参考文献：
  名称：

  WO2006/134378

  摘要：

  公开号：
• 作为产物：
  描述：

  4-氟-2-硝基苯胺 在 palladium on carbon 、 氢气 、 双氧水 、 sodium hydroxide 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 20.0~80.0 ℃ 、344.75 kPa 条件下， 反应 48.0h， 生成 7-氟-2(1H)-喹喔啉酮
  参考文献：
  名称：

  Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa

  摘要：

  Type II bacterial topoisomerases are well validated targets for antimicrobial chemotherapy. Novel bacterial type II topoisomerase inhibitors (NBTIs) of these targets are of interest for the development of new antibacterial agents that are not impacted by target-mediated cross-resistance with fluoroquinolones. We now disclose the optimization of a class of NBTIs towards Gram-negative pathogens, especially against drug-resistant Pseudomonas aeruginosa. Physicochemical properties (pKa and logD) were optimized for activity against P. aeruginosa and for reduced inhibition of the hERG channel. The optimized analogs 9g and 9i displayed potent antibacterial activity against P. aeruginosa, and a significantly improved hERG profile over previously reported analogs. Compound 9g showed an improved QT profile in in vivo models and lower clearance in rat over earlier compounds. The compounds show promise for the development of new antimicrobial agents against drug-resistant Pseudomonas aeruginosa.

  DOI：

  10.1016/j.bmc.2014.07.040

文献信息

• Iodine-Catalyzed C–N Bond Formation: Synthesis of 3-Aminoquinoxalinones under Ambient Conditions
  作者：Abhishek Gupta、Mahesh Subhashrao Deshmukh、Nidhi Jain

  DOI：10.1021/acs.joc.7b00464

  日期：2017.5.5

  cross-dehydrogenative coupling between quinoxalinones (sp2 C–H) and amines (N–H) in the presence of catalytic iodine is reported. The reaction yields 3-aminoquinoxalinones in moderate to high yields under ambient conditions in dioxane as solvent and aqueous tert-butyl hydroperoxide (TBHP) as the terminal oxidant. The reaction is highly versatile and exhibits good functional group tolerance with a range of primary

  据报道，在催化碘存在下，喹喔啉酮（sp 2 C–H）和胺（NH）之间无金属的交叉脱氢偶联。该反应在环境条件下，以二恶烷为溶剂，以叔丁基氢过氧化物水溶液（TBHP）作为末端氧化剂，以中等至高产率产生3-氨基喹喔啉。该反应是高度通用的，并且在一系列伯胺和仲胺中表现出良好的官能团耐受性。它为获得药物活性的3-氨基喹喔啉酮衍生物提供了实用途径。初步的机理研究表明，胺的原位碘化是假定的活化方式。
• Hepatitis C virus inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US09527885B2

  公开（公告）日：2016-12-27

  Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

  揭示了具有一般式（I）的丙型肝炎病毒抑制剂。还公开了包含这些化合物的组合物以及使用这些化合物抑制HCV的方法。
• Hepatitis C Virus Inhibitors
  申请人：Hiebert Sheldon

  公开号：US20130115190A1

  公开（公告）日：2013-05-09

  Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

  丙型肝炎病毒抑制剂具有通式（I）如下。还公开了包含这些化合物的组合物以及使用这些化合物抑制HCV的方法。
• [EN] QUINOXALINONES AND DIHYDROQUINOXALINONES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS<br/>[FR] QUINOXALINONES ET DIHYDROQUINOXALINONES EN TANT QU'AGENTS ANTIVIRAUX CONTRE VIRUS RESPIRATOIRE SYNCYTIAL
  申请人：JANSSEN R & D IRELAND

  公开号：WO2014114776A1

  公开（公告）日：2014-07-31

  Quinoxalinones and dihydroquinoxalinones having inhibitory activity on RSV replication and having the formula (I) including addition salts, and stereochemically isomeric forms thereof; compositions containing these compounds as active ingredient and processes for preparing these compounds and compositions.

  喹诺醌酮和二氢喹诺醌酮具有对RSV复制具有抑制活性的公式（I），包括加成盐和立体化学异构体形式；含有这些化合物作为活性成分的组合物以及制备这些化合物和组合物的过程。
• [EN] HETEROCYCLIC COMPOUNDS, IN PARTICULAR 2-OXO-4,4,5,5,6,6,7,7-OCTAHYDROBENZOXAZOLE DERIVATIVES, AND THEIR USE AS ANTIBACTERIAL COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES, EN PARTICULIER DÉRIVÉS DE 2-OXO -4,4,5,5,6,6,7,7-OCTAHYDROBENZOXAZOLE, ET LEUR UTILISATION EN TANT QUE COMPOSÉS ANTIBACTÉRIENS
  申请人：REDX PHARMA PLC

  公开号：WO2017137744A1

  公开（公告）日：2017-08-17

  This invention relates to antibacterial drug compounds containing a bicyclic core, typically a bicycle in which one of the rings is an oxazolidinone. It also relates to pharmaceutical formulations of antibacterial drug compounds. It also relates to uses of the compounds in treating bacterial infections and in methods of treating bacterial infections.

  这项发明涉及含有双环核心的抗菌药物化合物，通常是其中一个环是噁唑烷酮的双环。它还涉及抗菌药物化合物的药物配方。它还涉及化合物在治疗细菌感染和治疗细菌感染方法中的用途。